Takehara T - Search Results

1

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.

Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, Umemura T, Takehara T, Sakamoto N, Nishigaki Y, Nakane K, Toda N, Ide T, Yanase M, Hino K, Gao B, Garrison KL, Dvory-Sobol H, Ishizaki A, Omote M, Brainard D, Knox S, Symonds WT, McHutchison JG, Yatsuhashi H, Mizokami M. Omata M, et al. Among authors: takehara t. J Viral Hepat. 2014 Nov;21(11):762-8. doi: 10.1111/jvh.12312. Epub 2014 Sep 8. J Viral Hepat. 2014. PMID: 25196837 Clinical Trial.

2

HCV RNA and antibody to HCV core protein in Japanese patients with chronic liver disease.

Yuki N, Hayashi N, Hagiwara H, Takehara T, Kasahara A, Fusamoto H, Manabe S, Takamizawa A, Kamada T, Okayama H. Yuki N, et al. Among authors: takehara t. Dig Dis Sci. 1992 Oct;37(10):1483-8. doi: 10.1007/BF01296490. Dig Dis Sci. 1992. PMID: 1327684

3

A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C.

Sugimoto Y, Kuzushita N, Takehara T, Kanto T, Tatsumi T, Miyagi T, Jinushi M, Ohkawa K, Horimoto M, Kasahara A, Hori M, Sasaki Y, Hayashi N. Sugimoto Y, et al. Among authors: takehara t. J Viral Hepat. 2002 Sep;9(5):377-84. doi: 10.1046/j.1365-2893.2002.00365.x. J Viral Hepat. 2002. PMID: 12225333

4

Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.

Miyatake H, Kanto T, Inoue M, Sakakibara M, Kaimori A, Yakushijin T, Itose I, Miyazaki M, Kuzushita N, Hiramatsu N, Takehara T, Kasahara A, Hayashi N. Miyatake H, et al. Among authors: takehara t. J Viral Hepat. 2007 Jun;14(6):404-12. doi: 10.1111/j.1365-2893.2006.00814.x. J Viral Hepat. 2007. PMID: 17501761

5

Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts.

Okanoue T, Itoh Y, Minami M, Hashimoto H, Yasui K, Yotsuyanagi H, Takehara T, Kumada T, Tanaka E, Nishiguchi S, Izumi N, Sata M, Onji M, Yamada G, Okita K, Kumada H. Okanoue T, et al. Among authors: takehara t. Hepatol Res. 2008 Jan;38(1):27-36. doi: 10.1111/j.1872-034X.2007.00217.x. Hepatol Res. 2008. PMID: 18039201

6

Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan.

Umemura T, Tanaka E, Kiyosawa K, Kumada H; Japan de novo Hepatitis B Research Group. Umemura T, et al. Clin Infect Dis. 2008 Sep 1;47(5):e52-6. doi: 10.1086/590968. Clin Infect Dis. 2008. PMID: 18643758

7

Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.

Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K, Yoshioka K, Izumi N, Akuta N, Kumada H. Okanoue T, et al. Among authors: takehara t. J Gastroenterol. 2009;44(9):952-63. doi: 10.1007/s00535-009-0087-x. Epub 2009 Jun 11. J Gastroenterol. 2009. PMID: 19517057

8

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.

Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Oze T, et al. Among authors: takehara t. J Viral Hepat. 2009 Aug;16(8):578-85. doi: 10.1111/j.1365-2893.2009.01116.x. Epub 2009 Jun 22. J Viral Hepat. 2009. PMID: 19552663

9

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin.

Hiramatsu N, Oze T, Yakushijin T, Inoue Y, Igura T, Mochizuki K, Imanaka K, Kaneko A, Oshita M, Hagiwara H, Mita E, Nagase T, Ito T, Inui Y, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Hiramatsu N, et al. Among authors: takehara t. J Viral Hepat. 2009 Aug;16(8):586-94. doi: 10.1111/j.1365-2893.2009.01106.x. Epub 2009 Jun 22. J Viral Hepat. 2009. PMID: 19552664

10

Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.

Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hagiwara H, Oshita M, Mita E, Fukui H, Inada M, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Miyagi T, Hohsui A, Ishida H, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Inoue Y, et al. Among authors: takehara t. J Viral Hepat. 2010 May;17(5):336-44. doi: 10.1111/j.1365-2893.2009.01182.x. Epub 2009 Aug 12. J Viral Hepat. 2010. PMID: 19678893

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

835 results

Search Page